In this study, the healthy controls were approximately 12779 people. The prevalence of HBsAg was 6.6%, which was slightly lower than the reported proportion of HBsAg-positive patients in the general Chinese population (1). The lower HBV infection rate is probably due to the nationwide HBV vaccination program started in recent years. The proportion of females among the SLE patients (92.2%) was higher than that among the RA patients (81.3%). The mean age of onset of SLE and RA was 31.8±13.3 and 45.8±14.4 yr, respectively. This finding indicates that young female SLE patients are common in China, and the most RA patients are middle-aged to elderly females. HBV infection in patients with SLE was not frequently observed. The positive rate of HBsAg, indicating HBV infection, was significantly lower in patients with SLE (0.6%) than that in the healthy controls (6.6%). The HBsAg-positive rate was significantly higher in the patients with RA (7.1%) than in those with SLE (0.6%) and the healthy control (6.6%). The most remarkable findings were the low HBeAband HBcAb-positive rate in the patients with SLE compared with patients with RA. This finding may suggest a protective role of HBV in SLE as compared with RA. In the current study, the clinical parameters in SLE and RA patients were not associated with the presence of HBsAb and HBcAb. The presence of HBsAb may be the consequence of hepatitis B immunity instead of hepatitis B infection, and the presence of HBcAb, a seromarker of previous or current infection with HBV, may distinguish between infected and vaccinated populations, which include people, infected with or are now contracting HBV. Our preliminary findings suggest the absence of an association between hepatitis B vaccination or chronic HBV infection and levels of ANA, CRP, RF, CCP, DsDNA, C3, and disease activity in SLE and RA patients. Several researchers have proposed that the pathogenesis of HBVassociated arthritis is attributable to the deposition of immune complexes in synovial tissues (2, 3) . However, one study in RA patients found no association between chronic HBV infection and disease activity, synovitis, or joint destruction (4). In our study, the effects of hepatitis B immunity and past or current HBV infection on the clinical course of SLE and RA, if any, were relatively minor.
We found an extremely low prevalence of HBsAg in SLE patients and a high prevalence of HBsAg in RA patients compared with healthy controls. Additionally, there was no absence of association between hepatitis B vaccination and chronic HBV infection and disease activity in either the SLE or RA patients.
